This web site is part of the Business Intelligence Division of Informa PLC
This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.
Dr. Reddy's Laboratories
Drug Names(s): denileukin diftitox, Onzar, DAB389IL-2, E7272, E7777
Description: ONTAK is a fusion protein, consisting of a fragment of diphtheria toxin genetically fused to Interleukin-2. ONTAK targets IL-2 receptors on the surface of malignant cells and some normal lymphocytes, leading to the death of these cells.
Revenue splits for this drug are BioMedTracker estimates.
Ligand, Seragen and Lilly
Ligand acquired Seragen in 1998. In May 1998, Ligand signed an agreement with Eli Lilly and Company and Seragen, under which Lilly assigned to Ligand its rights and obligations under its agreements with Seragen, including its rights to ONTAK. Ligand's agreement with Lilly calls for up to $10 million in milestones.
In November 2004, Ligand restructured its agreement with Lilly with respect to the royalties payable to Lilly on sales of ONTAK in the United States. In January 2005, Ligand exercised the first option which provided for a one-time payment of $20 million to Lilly in exchange for the elimination of ONTAK royalty obligations in 2005, and a reduced, reverse-tiered royalty scale on ONTAK sales in the U.S. thereafter. In April 2005, Ligand exercised its final of two options under its November 2004 agreement with Lilly to buy down a further portion of the royalties payable...See full deal structure in Biomedtracker
Partners: Eli Lilly & Company Grupo Ferrer Internacional, S.A. Alfa Wassermann SpA Teva Pharmaceutical Industries Ltd. TSD Japan, Inc. Quintiles Transnational Holdings, Inc. Eisai Co., Ltd.
Pink Sheet FDA Warning Letter Targets Ligand Oncologics
Additional information available to subscribers only: